Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 184

Results For "disease"

2059 News Found

Lupin enters Guinness Records highlights rise in strokes
Public Health | October 25, 2021

Lupin enters Guinness Records highlights rise in strokes

This unique record was made possible by collating hard copies of the books in a structured manner


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Roche’s Susvimo, for `wet’ age-related macular degeneration (nAMD) approved
Drug Approval | October 25, 2021

Roche’s Susvimo, for `wet’ age-related macular degeneration (nAMD) approved

The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months


Novartis cancer drug trial does not meet primary end points
Biotech | October 25, 2021

Novartis cancer drug trial does not meet primary end points

The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan


Zydus announces update on a randomised trial of Saroglitazar Mg in NASH
Biotech | October 22, 2021

Zydus announces update on a randomised trial of Saroglitazar Mg in NASH

Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders


WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
Biotech | October 22, 2021

WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services

It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China


U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years
Drug Approval | October 22, 2021

U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option


MediBuddy records a steep increase in dermatology consultation amongst youngsters
Startup | October 22, 2021

MediBuddy records a steep increase in dermatology consultation amongst youngsters

The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues


Global Heart Hub and Novartis partner to tackle ASCVD
Public Health | October 21, 2021

Global Heart Hub and Novartis partner to tackle ASCVD

Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care


Boehringer Ingelheim and partners to develop gene therapy for patients with cystic fibrosis
Biotech | October 21, 2021

Boehringer Ingelheim and partners to develop gene therapy for patients with cystic fibrosis

It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology